{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:08:06Z","timestamp":1788188886638,"version":"build-2803163510"},"reference-count":52,"publisher":"Korean Association of Internal Medicine","issue":"5","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100019547","name":"Korean Society of Lipid and Atherosclerosis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019547","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and &lt; 70 or &lt; 55 mg\/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C &gt; 500 mg\/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.<\/jats:p>","DOI":"10.3904\/kjim.2022.121","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T01:46:11Z","timestamp":1658886371000},"page":"931-944","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["2022 Consensus statement on the management of familial hypercholesterolemia in Korea"],"prefix":"10.3904","volume":"37","author":[{"given":"Chan Joo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjae","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-3745","authenticated-orcid":true,"given":"Sang-Hak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Task Force Team for Familial Hypercholesterolemia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Korean Society of Lipid and Atherosclerosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2270","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh236"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw028"},{"key":"ref3","first-page":"558","volume-title":"A case of familial hypercholesterolemia combined with diabetes mellitus","author":"Lee","year":"1989"},{"key":"ref4","first-page":"1288","volume-title":"A case of familial hypercholesterolemia","author":"You","year":"1989"},{"key":"ref5","first-page":"140","volume-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","year":"2019"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5551\/jat.cr003"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5551\/jat.63062"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.024379"},{"key":"ref9","first-page":"3478","volume-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","author":"Nordestgaard","year":"2013"},{"key":"ref10","first-page":"2889","volume-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2014"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.024541"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.08.033"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-316276"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5551\/jat.14159"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.09.005"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2008.135"},{"key":"ref17","first-page":"662","volume-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","author":"Sturm","year":"2018"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx004"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2021.09.012"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23634"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126706"},{"key":"ref22","volume-title":"Disorders of lipoprotein metabolism","author":"Rader","year":"2018"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5551\/jat.rv17052"},{"key":"ref24","first-page":"131","volume-title":"Combined hyperlipidemia: familial but not (usually) monogenic","author":"Brahm","year":"2016"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu274"},{"key":"ref26","first-page":"217","volume-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","author":"Wilemon","year":"2020"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2019.8.2.78"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.859"},{"key":"ref29","first-page":"e285","volume-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2019"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22826"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75901-0"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2423"},{"key":"ref33","first-page":"252","volume-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","author":"Besseling","year":"2016"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61350-5"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1410489"},{"key":"ref36","first-page":"495","volume-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","author":"Tsujita","year":"2015"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2021.10.3.291"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1615664"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801174"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx549"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5551\/jat.45229"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60284-x"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61731-0"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1913805"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2031049"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004215"},{"key":"ref47","first-page":"1713","volume-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","year":"2021"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(16)30041-9"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000297"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv157"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2019910"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1097\/mol.0000000000000790"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/kjim.org\/upload\/kjim-2022-121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2022.121","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/upload\/kjim-2022-121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T06:35:21Z","timestamp":1662446121000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2022.121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2022.121","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"2022-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}